BME Seminar: Immune Checkpoints in Type 1 Diabetes

Published: August 28th, 2017

Category: Seminars

Loading Map....


3:00 pm-4:00 pm
Add to Outlook/iCal
Add to Google Calendar


Communicore Room C1-17


Todd M. Brusko, Ph.D., Associate Professor, Diabetes Institute, College of Medicine, University of Florida

Dr. Brusko will discuss human immune heterogeneity in type 1 diabetes and potential applications of biomedical engineering for the restoration of immune tolerance.

Dr. Brusko is currently appointed as an Associate Professor within the Diabetes Institute at the University of Florida, College of Medicine. The research interests of his academic lab are centrally themed around understanding the mechanisms by which the immune system maintains a state of control, often referred to as immunological tolerance. A portion of his lab is dedicated to understanding how genetic risk variants influence this process, as well as identifying pathway defects in individuals who develop autoimmune diseases. These studies have focused primarily on genes impacting key checkpoints in T cell activation, including TCR signaling, co-stimulation, and the IL2R pathway.

Dr. Brusko’s laboratory currently serves as the advanced cytometry and cell sorting core for the JDRF-sponsored National Pancreatic Organ donors with Diabetes (nPOD) program. He is an active member of the Helmsley Charitable Trust Team Science Initiative and has a number of ongoing projects to gain a better understanding of the immune repertoire at the site of autoimmune attack through immunosequencing and phenotypic assessments of tissue-resident lymphocytes.

Dr. Brusko has published 60 scientific papers reporting on the genetic and molecular basis of defects in immune regulation in autoimmune diseases. A central theme of Dr. Brusko’s research involves dissecting heterogeneity in human immune development and conducting immune phenotypic monitoring in a number clinical intervention trials in T1D. Dr. Brusko serves on review committees for the NIH TrialNet ancillary studies panel, JDRF Biomarkers and Mechanisms Panel (BMP), and scientific review panel of the Helmsley T1D Exchange.